Chronic central pain is a frequent complication after spinal cord injury. Anticonvulsant drugs, among them valproate, have been recommended for treatment. In this paper we conducted a double-blind, cross-over study compar ing valproate and placebo for severe chronic central pain. During the study, serum concentration of valproate, pain and side effects were registered and the dose was adjusted according to these. No significant analgesic effects of valproate could be demonstrated although serum concentration and dose reached a high level. Few studies of pain following spinal cord injury exist and we recommend that further studies be performed.
Introduction
Intractable pain is a frequent sequel after spinal cord injury (SCI). The incidence of chronic pain following SCI ranges from 6 to 94% according to various authors.1-4 Cor respondingly, in a previous study we found frequent pain reported by 66% of the patients.5 According to most authors 2 .6 painful sensations after SCI are divided into (1) root pain, (2) visceral pain and (3) central pain or phantom body pain. Central pain felt below the level of the lesion is the commonest form and treatment is very difficult. Surgical treatment is of limited value,6,7 and conventional analgesics have not been of much assistance. Antiepi leptic medications such as carbamazepine have been recommended,7 and during the last years sodium valproate has been used for the treatment of central pain with good results in some patients, The aim of this study was to conduct a double-blind, placebo controlled study of valproate for the treatment of chronic central pain following SCI.
Methods
The study was performed from August 1990 to May 1991. All potential subjects were either hospitalised or were outpatients at the spinal cord injury centre who had a complaint of pain and were referred to one of the physicians, who performed a pre liminary telephone screening evaluation. Patients who met the study criteria were invited to participate in the research project. A total of 20 patients agreed to do so: they were all outpatients except three, who were hospitalised in the spinal cord injury centre for some of the weeks during treatment.
Included were patients older than 18 years with nonprogressive SCI and central pain lasting for more than 1 month. All patients had failed to respond to conven tional treatments. Central pain was defined as pain distal to the level of injury in an area with loss of normal feeling. 2 ,7 Excluded were patients with severe obesity or liver disease, pregnant women, patients treated with anticoagulant drugs, phenobarbital or primidone, and patients with known intoler ance to valproate.
The study was a double-blind, cross-over study with the first treatment period of 3 weeks with valproate or placebo followed by a 'wash-out' period of 2 weeks and a new 3 week treatment period (Fig 1) . Patients were interviewed and had 1 hour's instruc tion at baseline by one of the authors Weeks Figure 1 The cross-over design.
(AMD) who undertook the further adjust ment of medicine during the treatment.
Weekly telephone assessments and contact to the patients were performed by the other two authors, who did not know which treatment the patients had received. A written report of the patient's current pain status on a 1-5 verbal scale, side effects and consumption of medicine was delivered to AMD after each telephone assessment (Fig 2) . Thereby the double-blind procedure was confirmed. Every week serum concen tration of valproate and liver function tests were done and the medicine was adjusted by AMD according to the following procedure (Fig 2) . Following randomisation patients began treatment with 600 mg val pro ate or a cor responding placebo tablet b.i.d. If patients had consumption of other analgesics, the dose was kept constant during the study. Laboratory examinations and telephone assessments were made after 5 days. If the patient still had pain, if no side effects had occurred and if the serum concentration was less than 650 {lmol/!, the daily dose was individually increased depending on the serum concentration, body weight and cur- 
Statistics
Nonparametric methods were used for the statistical analysis. As in every cross-over
Final evaluation at telephone assessment and filling in MPQ design there is a risk of a 'carry-over' effect as well as 'regression towards the mean'. The Mann-Whitney test was used for ana lysing carry-over effects comparing the effect of treatment in period X l + Y 2 and YI + X 2 in the two series (Fig 1) . The same test was used for analysing regression towards the mean comparing the effect in period X l -Y 2 and X 2 -Y I' l O Treatment ef fect was analysed using the Wilcoxon matched-pair rank test or Pratt's test with difference scores of zero.
Results
All 20 patients, 15 males and five females, completed the study. Sixteen were paraple gic and four tetraplegic. One patient had SCI due to spinal stenosis, the others all had a traumatic cause. Median age was 32.5 years (18-75) and median time after SCI was 79.5 months (4-122). One patient filled in the MPQ wrongly in the valproate period and these data were omitted from the statistical analysis. Pain started a few months after SCI in all of the patients, and they had all tried various other forms of analgesics without benefit. All pain sensa tions were distal to the level of the lesion. The words describing pain most frequently chosen from the baseline MPQ were tingling (55% ), shooting (50%), agonising (45%), cutting and cruel (40%). One patient had only 2 weeks of valproate treatment (daily dose was 1800 mg and serum concentration was 748,umol/l) as gastroenteritis occurred; liver function tests were normal, and retro spectively we do not believe that the gastro enteritis was a side effect. Four patients in the val pro ate series had side effects (dizzi ness), and the dose was not increased further. None of the patients in the placebo Treatment of central pain after SCI 567 series had side effects. All laboratory exami nations were normal.
In the statistical analysis no evidence of carry-over effect or regression towards the mean was observed, indicating that the study design was acceptable. After 3 weeks of treatment six patients in the valproate series improved and two had worsening of the pain. In the placebo series four patients improved and one was worse. The median dose of valproate was 1800 mg (600-2400) and median. serum concentration was 614,umol/l (128-999). The results from the telephone assessments and the MPQ sub scores are given in Table I . No significant differences were observed comparing pa tients in the valproate and placebo series, although a trend towards improvement was observed in most subgroups during valpro ate treatment.
Discussion
Chronic central pain is a frequent complica tion following SCI. Various authors have recommended anticonvulsant drugs7,1 l for its treatment. This is in accordance with the belief that central pain is a variety of deafferentation pain, similar to the pain seen in patients with peripheral nerve, thalamic and parietal lobe lesions.1 2 There is convincing evidence that the deafferenta tion produces abnormal physiological activ ity in spinal and brain cells deprived of normal sensory input, and these cells fire spontaneously.6,13 Thus anticonvulsivant drugs are a rational pharmacological ap proach. Moreover, valproate has GABA ergic mechanisms within the CNS,14 and several studies both in animals and in humans have provided evidence for a link between GABA-ergic mechanisms and the For abbreviations, see text.
opioid system. However, few studies have been conducted to demonstrate the analgesic effects of valproate1S-17 and to the authors' knowledge no studies of the use of anticonvulsive drugs for pain following SCI exist.
In this study we could not demonstrate significant analgesic effects of valproate. The study group had severe tingling, shoot ing and cutting pain below the level of injury with pain onset a few months after SCI, which is typical for central pain. 2 , 18 The pain was severe and constant, and several analgesics were tried without benefit, con firming that the management of pain in this patient group should be considered to be difficult. The dose of valproate was con sidered sufficient for effect as serum concen trations reached the upper limit during the last treatment week in most patients; thus a beneficial effect should be expected. Thirty three per cent improved during valproate treatment, but no statistically significant effect was observed compared to the placebo series. In any event, four patients wished to continue with val pro ate therapy after the study, and some patients might benefit from the treatment, although our results could not demonstrate a significant References Paraplegia 32 (1994) 565-569 effect. The risk of a type II error must be considered when the number of patients is taken into account, but to eliminate this risk at least 150 patients would require to be included, which is not realistic.
In the treatment of chronic central pain after SCI, anticonvulsant drugs,7' I l.l 7 antide pressants19, 2 0 and transcutaneous nerve stimulation7, 2 1 have been recommended. Moreover, a recent study 22 reported successful treatment with amitriptyline and carbamazepine, and drug combinations may be of value in some patients. There is, however, agreement that the presently available pharmacological agents for pain management are most effective in patients with mild or moderate pain. In general, valproate cannot be recommended for severe central pain. Few studies of pain following SCI exist, although the disorder is very common, and we recommend that further studies with larger groups of patients be performed.
